Lowey Dannenberg, P.C. is investigating The Ensign Group for potential violations of federal securities laws following reports accusing the company of falsifying care-quality data and Medicare fraud. These allegations led to significant stock price drops and shareholder losses. The investigation aims to determine if the company misled investors with inaccurate information. Investors who suffered losses can check eligibility to participate in legal action through the firm's platform.
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...
LiveOne announced it will release its first quarter fiscal 2027 financial results on August 12, 2026, with a conference call to discuss the performance. The company expects continued year-over-year growth in revenue and adjusted EBITDA, driven by org...
Immix Biopharma appointed Richard Graydon as Chief Medical Officer in March 2026, but he was terminated in July after it was revealed he was actually Ronald L. Fischer, a fugitive wanted since 2005 for rape charges. This revelation led to a 14.15% dr...
Robert W. Baird lowered its price target for Fidelity National Information Services (FIS) from $54.00 to $48.00 following the company's mixed Q2 2026 earnings report. FIS posted strong adjusted EPS of $1.48, beating estimates and showing 8.8% growth ...
Uber Technologies continues to lead the U.S. ridesharing market with about 75% share, while expanding its food delivery and advertising businesses. Despite Waymo, Alphabet's self-driving unit, planning to compete directly by launching its own ride-ha...
